COVID19

Noxopharm CEO Discusses SOF-VAC™, a Promising Vaccine Enhancer for mRNA Vaccines

In an interaction with BioPharma APAC, Noxopharm CEO Dr. Gisela Mautner discussed the company's newly announced proprietary product candidate, SOF-VAC&trad...

 March 31, 2023 | Influencers

YS Biopharma's PIKA COVID-19 Vaccine Shows Better Antibody Response Than Inactivated Vaccine in Phase II Study

The trial met its primary endpoint of superior immunogenicity of PIKA COVID-19 Vaccine vs inactivated COVID-19 vaccine, measured by GMT of neutralizing a...

 March 28, 2023 | News

World TB Day 2023: Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics company, have launched...

 March 24, 2023 | News

GenScript ProBio and RVAC Medicines Partner for COVID-19 Vaccine Plasmid DNA Manufacturing

GenScript ProBio will provide GMP plasmid manufacturing service for RVAC Medicines' program, RVM-V001. This partnership will enable to accelerate its clini...

 February 23, 2023 | News

RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore

The clinical trial aims to evaluate three of RVAC's COVID-19 vaccine candidates that include one against the ancestral strain, one against an Omicron strai...

 February 21, 2023 | News

Leveraging Digital Technologies Can Help Grow Strong and Sustainable Communities

In 2020, global poverty increased for the first time since the Asian financial crisis of the late 1990s because of the effects of the COVID-19 pandemic. Be...

 February 13, 2023 | News

Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant

This new test for researchers specifically targets the XBB.1.5 Omicron sub-variant and runs on the real-time PCR platforms LightCycler® 480 II* ...

 January 30, 2023 | News

China monitors coronavirus mutations to adjust COVID-19 response

"It is a worry," said CNN, citing William Schaffner, professor at the Division of Infectious Diseases of Vanderbilt University Medical Cente...

 January 02, 2023 | News

Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19

GS221 has conducted 3 clinical trials. Current results of clinical trials show favorable safety and tolerance in the subjects. After administra...

 January 02, 2023 | News

Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

The dose-confirming trial will evaluate the safety and effectiveness (immunogenicity) of different formulations of the CIC and influenza vaccine candidates...

 January 02, 2023 | News

China to downgrade COVID-19 management to Class B

In a statement released late Monday, the National Health Commission (NHC) renamed the Chinese term for COVID-19 from "novel coronavirus pneumonia" to "nove...

 December 28, 2022 | News

China Covid19 Surge : Coronavirus Pandemic Country Profile

What is important to note about these case figures? The reported case figures on a given date do not necessarily show the number of new cases on that da...

 December 22, 2022 | News

Pictor announces important COVID-19 trial to map immunity profile of New Zealanders

Pictor, a global leader in immunodiagnostics, today announced an important research project – the Pictor Antibody Clinical Trial (PACT-19) – wh...

 December 22, 2022 | News

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically valida...

 December 15, 2022 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close